2025 年 74 巻 10 号 p. 915-927
Magnolia officinalis Flos (Houpohua), a valued traditional Chinese medicine, suffers from inconsistent quality due to vague pharmacopeial harvesting criteria. To resolve this, we integrated multi-scale analytical approaches—including microscopic histochemistry, gas chromatography-mass spectrometry (GC-MS), and chemometrics (n=120 samples)—yielding three critical discoveries: (1) A newly established 4-stage developmental classification (S1-S4) pinpointed S1 (bud length: 4.1–6.0 cm) as the biosynthetic optimum, exhibiting peak essential oil content (0.27% w/w) and maximal oil cell density (236.35 ± 7.09 cells/mm2); (2) Spatial mapping revealed a 40.03-foldoil cell gradient between basal (115.29 ± 3.45 cells/mm2) and apical tepal regions, indicating tissue-specific accumulation patterns; (3) Multivariate analysis uncovered a developmental metabolic shift dominated by caryophyllene-to-caryophyllene oxide conversion (explaining 94.06% of PC1 variance), synchronized with oil cell maturation. Mechanistically, post-S1 yield reduction stems from cell dilution (tepal expansion) and oxidative transformation. This work not only establishes evidence-based harvesting standards but also proposes a novel quality assessment paradigm integrating structural and metabolic markers for medicinal plants.
